News
-
-
-
PRESS RELEASE
Inside Information / News release on accounts, results
GenSight Biologics reports cash position of €6.9 million as of June 30, 2024, with potential over 100 vials available upon Q3 resumption of early access program. Company confirms sufficient working capital and successful blending step for LUMEVOQ drug product -
-
REGULATED PRESS RELEASE
Thales publie ses résultats semestriels 2024
-
REGULATED PRESS RELEASE
Thales reports its 2024 half-year results
-
-
-
-